{
"info": {
"nct_id": "NCT02526823",
"official_title": "Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma",
"inclusion_criteria": "1. Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;\n2. Ages ≥18 years old, < 80 years old;\n3. ECOG (Eastern Cooperative Oncology Group)score: 0-2\n4. At least one measurable lesion;\n5. Expected survival time≥3 months;\n6. Liver function: transaminase≤2.5× upper limit of normal value,bilirubin≤1.5×upper limit of normal value;\n7. Renal function: serum creatinine is 44-133 mmol/L;\n8. Routine blood test:WBC≥3.0×109/L,Neutrophils≥1.5×109/L,Hb≥100g/L,Platelet≥80×109/L; LVEF≥50%;\n9. New York Heart Association (NYHA) heart function classification is I-II grade\n10. signed informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
"exclusion_criteria": "1. Patients with severe complications or severe infection;\n2. Invasion of central nervous system;\n3. Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;\n4. patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;\n5. patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;\n6. Patients participate in other clinical studies;\n7. Other patients who are not suitable for the study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;",
"criterions": [
{
"exact_snippets": [
"Primary B-NHL"
],
"criterion": "B-NHL",
"requirement_type": "type",
"expected_value": "primary"
},
{
"exact_snippets": [
"PTCL"
],
"criterion": "PTCL",
"requirement_type": "type",
"expected_value": true
},
{
"exact_snippets": [
"ALK+ anaplastic large cell lymphoma",
"excluded"
],
"criterion": "ALK+ anaplastic large cell lymphoma",
"requirement_type": "exclusion",
"expected_value": true
},
{
"exact_snippets": [
"NK(natural killer cell )/T cell lymphoma",
"excluded"
],
"criterion": "NK/T cell lymphoma",
"requirement_type": "exclusion",
"expected_value": true
},
{
"exact_snippets": [
"HL patients"
],
"criterion": "HL",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"confirmed by histopathology"
],
"criterion": "histopathology confirmation",
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"line": "2. Ages ≥18 years old, < 80 years old;",
"criterions": [
{
"exact_snippets": [
"Ages ≥18 years old"
],
"criterion": "age",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18
}
]
}
},
{
"exact_snippets": [
"< 80 years old"
],
"criterion": "age",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 80
}
]
}
}
]
},
{
"line": "3. ECOG (Eastern Cooperative Oncology Group)score: 0-2",
"criterions": [
{
"exact_snippets": [
"ECOG (Eastern Cooperative Oncology Group)score"
],
"criterion": "ECOG score",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0
},
{
"operator": "<=",
"value": 2
}
]
}
}
]
},
{
"line": "4. At least one measurable lesion;",
"criterions": [
{
"exact_snippets": [
"At least one measurable lesion"
],
"criterion": "measurable lesion",
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1
}
}
]
},
{
"line": "5. Expected survival time≥3 months;",
"criterions": [
{
"exact_snippets": [
"Expected survival time",
"≥3 months"
],
"criterion": "survival time",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3
}
]
}
}
]
},
{
"line": "6. Liver function: transaminase≤2.5× upper limit of normal value,bilirubin≤1.5×upper limit of normal value;",
"criterions": [
{
"exact_snippets": [
"Liver function: transaminase≤2.5× upper limit of normal value"
],
"criterion": "transaminase",
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2.5
}
]
}
},
{
"exact_snippets": [
"bilirubin≤1.5×upper limit of normal value"
],
"criterion": "bilirubin",
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 1.5
}
]
}
}
]
},
{
"line": "7. Renal function: serum creatinine is 44-133 mmol/L;",
"criterions": [
{
"exact_snippets": [
"Renal function: serum creatinine is 44-133 mmol/L"
],
"criterion": "serum creatinine",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 44
},
{
"operator": "<=",
"value": 133
}
]
}
}
]
},
{
"line": "8. Routine blood test:WBC≥3.0×109/L,Neutrophils≥1.5×109/L,Hb≥100g/L,Platelet≥80×109/L; LVEF≥50%;",
"criterions": [
{
"exact_snippets": [
"Routine blood test",
"WBC≥3.0×109/L"
],
"criterion": "white blood cell",
"requirement_type": "count",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3.0
}
]
}
},
{
"exact_snippets": [
"Routine blood test",
"Neutrophils≥1.5×109/L"
],
"criterion": "neutrophils",
"requirement_type": "count",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1.5
}
]
}
},
{
"exact_snippets": [
"Routine blood test",
"Hb≥100g/L"
],
"criterion": "hemoglobin",
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 100
}
]
}
},
{
"exact_snippets": [
"Routine blood test",
"Platelet≥80×109/L"
],
"criterion": "platelet",
"requirement_type": "count",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 80
}
]
}
},
{
"exact_snippets": [
"LVEF≥50%"
],
"criterion": "left ventricular ejection fraction",
"requirement_type": "percentage",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 50
}
]
}
}
]
},
{
"line": "9. New York Heart Association (NYHA) heart function classification is I-II grade",
"criterions": [
{
"exact_snippets": [
"New York Heart Association (NYHA) heart function classification"
],
"criterion": "NYHA heart function classification",
"requirement_type": "grade",
"expected_value": [
"I",
"II"
]
}
]
},
{
"line": "10. signed informed consent.",
"criterions": [
{
"exact_snippets": [
"signed informed consent"
],
"criterion": "informed consent",
"requirement_type": "signed",
"expected_value": true
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": [
"Healthy volunteers allowed"
],
"criterion": "healthy volunteers",
"requirement_type": "participation",
"expected_value": true
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": [
"minimum age of 18 Years"
],
"criterion": "age",
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18
}
}
]
},
{
"line": "Must have maximum age of 80 Years",
"criterions": [
{
"exact_snippets": [
"maximum age of 80 Years"
],
"criterion": "age",
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 80
}
}
]
}
],
"exclusion_lines": [
{
"line": "1. Patients with severe complications or severe infection;",
"criterions": [
{
"exact_snippets": [
"severe complications"
],
"criterion": "complications",
"requirement_type": "severity",
"expected_value": "severe"
},
{
"exact_snippets": [
"severe infection"
],
"criterion": "infection",
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"line": "2. Invasion of central nervous system;",
"criterions": [
{
"exact_snippets": [
"Invasion of central nervous system"
],
"criterion": "central nervous system",
"requirement_type": "invasion",
"expected_value": true
}
]
},
{
"line": "3. Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;",
"criterions": [
{
"exact_snippets": [
"severe heart disease history"
],
"criterion": "heart disease",
"requirement_type": "severity",
"expected_value": "severe"
},
{
"exact_snippets": [
"ventricular tachycardia (VT)"
],
"criterion": "ventricular tachycardia",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"atrial fibrillation (AF)"
],
"criterion": "atrial fibrillation",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"heart block"
],
"criterion": "heart block",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"myocardial infarction (MI)"
],
"criterion": "myocardial infarction",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"congestive heart failure (CHF)"
],
"criterion": "congestive heart failure",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"coronary heart disease",
"needed therapy"
],
"criterion": "coronary heart disease",
"requirement_type": "therapy requirement",
"expected_value": true
}
]
},
{
"line": "4. patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;",
"criterions": [
{
"exact_snippets": [
"severe allergic constitution"
],
"criterion": "allergic constitution",
"requirement_type": "severity",
"expected_value": "severe"
},
{
"exact_snippets": [
"allergic to",
"drug composition in chemotherapy regimens"
],
"criterion": "allergy",
"requirement_type": "presence",
"expected_value": "drug composition in chemotherapy regimens"
},
{
"exact_snippets": [
"intolerant of",
"drug composition in chemotherapy regimens"
],
"criterion": "intolerance",
"requirement_type": "presence",
"expected_value": "drug composition in chemotherapy regimens"
},
{
"exact_snippets": [
"other malignant tumors",
"in the past 5 years"
],
"criterion": "malignant tumors",
"requirement_type": "history",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5
}
]
}
}
]
},
{
"line": "5. patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;",
"criterions": [
{
"exact_snippets": [
"patients received doxorubicin therapy"
],
"criterion": "doxorubicin therapy",
"requirement_type": "receipt",
"expected_value": true
},
{
"exact_snippets": [
"total cumulative dose of adriamycin was more than 300 mg/m2"
],
"criterion": "adriamycin",
"requirement_type": "cumulative dose",
"expected_value": {
"operator": ">",
"value": 300
}
},
{
"exact_snippets": [
"total cumulative dose of epirubicin was more than 450 mg/m2"
],
"criterion": "epirubicin",
"requirement_type": "cumulative dose",
"expected_value": {
"operator": ">",
"value": 450
}
}
]
},
{
"line": "6. Patients participate in other clinical studies;",
"criterions": [
{
"exact_snippets": [
"Patients participate in other clinical studies"
],
"criterion": "participation in other clinical studies",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "7. Other patients who are not suitable for the study.",
"criterions": [
{
"exact_snippets": [
"Other patients who are not suitable for the study"
],
"criterion": "suitability for the study",
"requirement_type": "suitability",
"expected_value": false
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}